Modern Possibilities of Usage Dupilumab in Children

Dupilumab is a genetically engineered immunobiological drug that has been increasingly used in recent years to treat bronchial asthma (BA), atopic dermatitis (AD) and eosinophilic esophagitis (EE) in children. The aim of the study is to analyze current literature data on the use of dupilumab in the treatment of BA, AD and EE in children. Despite the short history of dupilumab use in the pediatric population, its usage has shown promising results in the treatment of many conditions whose pathogenesis is T2 inflammation, primarily BA, AD and EE. It has demonstrated efficacy in patients with various clinical manifestations characterized by moderate to severe course or refractory to treatment, and has led to an improvement in the quality of life of patients. With the expansion of the use of dupilumab, there is more and more evidence of its usefulness in the treatment of other T-cell-mediated diseases.

1. Konnov РЕ, Arsenieva AA. Efficacy and safety of the first targeted bioiogicai drug dupiiumab in the treatment of severe continuousiy reiapsing atopic dermatitis. Vestnik Dermatologii i Venerologii. 2023;99(l):62-70. (In Russ), https://doi.org/10.25208/vdvl384]

2. Churyukina EV. Dupiiumab: aspects of use in severe bronchiai asthma in reai ciinicai practice. Prakticheskaya pulmonologiya. 2022;(2):3-10. (In Russ), https://doi.org/10.24412/2409-6636-2022-12937

3. Giukhova EA, Kuvshinova ED, Revyakina VA. Experiencewith dupiiumab in patients with atopic dermatitis. Allergology and Immunology in Paediatrics. 2022;(3):14-23. (In Russ), https://doi.org/10.53529/2500-1175-2022-3-14-23

4. Drugs@FDA: FDA-Approved Drugs, in: U.S. Food & Drug Administration. Available online: https://www.accessdata.fda.gov/scripts/cder/daf. Accessed on November 08, 2024.

5. Augustin M, Bauer A, Ertner K, et al. Dupiiumab Demonstrates Rapid Onset of Action in Improving Signs, Symptoms and Quality of Life in Adults with Atopic Dermatitis. Dermatol Ther (Heidelb). 2023;13(3):803-816. https://doi.org/10.1007/sl3555-023-00894-3

6. SilverbergJI, BarbarotS, Gadkari A, etal. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2. https://doi.org/10.1016/J.anai.2020.12.020

7. Potekaev NN, Serov DN, Mikhailova IA, et al. Current aspects of pathogenesis and treatment of atopic dermatitis. Russian Journal of Clinical Dermatology and Venereology = Klinicheskaya dermatologiya I venerologlya. 2019;18(3):259-263. (In Russ), https://doi.org/10.17116/klinderma201918031259

8. Paller AS, Weidinger S, Capozza K, et al. Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey). Dermatol Ther (Heidelb). 2023;13(4):961-980. https://doi.org/10.1007/sl3555-022-00850-7

9. Flarb FI, Chatila TA. Mechanisms of Dupiiumab. Clin Exp Allergy. 2020;50(1):5-14. https://doi.org/10.llll/cea.13491

10. Flamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupiiumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J A/Zergy CTin Immunol. 2014;134(6):1293-1300. https://doi.org/10.1016/J.Jaci.2014.10.013

11. Wang A, Zhou Y, Luo Y, et al. Fligh loading-dose of dupiiumab resulted in rapid disease control in pediatric patients with atopic dermatitis. Front Immunol. 2023;14:1160710. https://doi.org/10.3389/fimmu.2023.1160710

12. BlauveltA, Guttman-YasskyE, Paller AS, etal. Long-Term Efficacy and Safety of Dupiiumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365-383. https://doi.org/10.1007/s40257-022-00683-2

13. Ferrucci S, Casazza G, Zussino M, et al. Predictive Factors of Early Response to Dupiiumab in Patients with Moderate-to-Severe Atopic Dermatitis. J Clin Med. 2023;12(20):6575. https://doi.org/10.3390/Jcml2206575

14. Kim EJ, Hlobik M, Ho T. Effectiveness of dupiiumab in pediatric patients with a nummular phenotype of atopic dermatitis. Pediatr Dermatol. 2024;41(3):455-457. https://doi.org/10.llll/pde.15541

15. Kim JW, Kim M, Ahn GS, Na Jl. Dupilumabprovidesrapid improvement for morphologic variants of paediatric atopic dermatitis: A case series. Indian J Dermatol Venereol Leprol. 2022;88(6):834-839. https://doi.org/10.25259/IJDVL_759_2021

16. Gelato F, Mastorino L, Stepkina E, et al. Is Dupiiumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis? J Clin Med. 2023;12(6):2189. https://doi.org/10.3390/Jcml2062189

17. Murashkin NN, Opryatin LA, Pavlova ES, et al. Dupiiumab Efficacy and Safety in Severe Atopic Dermatitis in Children under 6 Years of Age: Two Clinical Cases. Voprosy sovre-mennoi pediatrii — Current Pediatrics. 2023;22(5):443-449. (In Russ), https://doi.org/10.15690/vsp.v22i5.2622

18. Kamphuis E, BoesJes CM, Loman L, et al. Dupiiumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry. Pediatr Allergy Immunol. 2022;33(12):el3887. https://doi.org/10.1111/pai.l3887

19. Paller AS, Simpson EL, Siegfried EC, et al. Dupiiumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908-919. https://doi.org/10.1016/S0140-6736(22)01539-2

20. Paller AS, Siegfried EC, Thaęi D, et al. Efficacy and safety of dupiiumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282-1293. https://doi.0rg/lO.lOl6/J.Jaad.2020.06.054

21. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupiiumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(l):44-56. DOI: 10.1001/Jamadermatol.2019.3336

22. Siegfried EC, Simpson EL, Cork MJ, et al. Dupiiumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years. Dermatol Ther (Heidelb). 2023;13(9):1987-2000. https://doi.org/10.1007/sl3555-023-00960-w

23. Paller AS, Bansal A, Simpson EL, et al. Clinically Meaningful Responsesto Dupiiumab In Adolescentswith Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2020;21(1):119-131. https://doi.org/10.1007/s40257-019-00478-y

24. Cork MJ, Lockshin B, Pinter A, et al. Clinically Meaningful Responses to Dupiiumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial. Acta Derm Venereol. 2024;104:advl3467. https://doi.org/10.2340/actadv.vl04.13467

25. Siegfried EC, Cork MJ, Katoh N, et al. Dupiiumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial. Am J Clin Dermatol. 2023;24(5):787-798. https://doi.org/10.1007/s40257-023-00791-7

26. Siegfried EC, Bieber T, Simpson EL, et al. Effect of Dupiiumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Am J Clin Dermatol. 2021;22(2):243-255. https://doi.org/10.1007/s40257-020-00583-3

27. Paller AS, Wollenberg A, Siegfried E, et al. Laboratory Safety of Dupiiumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. Paediatr Drugs. 2021;23(5):515-527. https://doi.org/10.1007/s40272-021-00459-x

28. Paller AS, Siegfried EC, Cork MJ, et al. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatr Drugs. 2023;25(1):67–77. https://doi.org/10.1007/s40272-022-00553-8

29. Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2021;184(5):857–870. https://doi.org/10.1111/bjd.19460

30. Paller AS, Siegfried EC, Simpson EL, et al. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study. Am J Clin Dermatol. 2024;25(4):655–668. https://doi.org/10.1007/s40257-024-00859-y

31. Global Burden of Disease due to Asthma. In: The Global Asthma Report 2022. Available online: http://www.globalas-thmareport. org/burden/burden.php. Accessed on November 08, 2024.

32. Byalovskiy YuYu, Glotov SI, Rakitina IS, Ermachkova AN. Pathogenetic Aspects of Bronchial Asthma Phenotyping. I.P. Pavlov Russian Medical Biological Herald. 2024;32(1):145–158. (In Russ). https://doi.org/10.17816/PAVL0VJ181606

33. Ricciardolo FLM, Bertolini F, Carriero V. The Role of Dupilumab in Severe Asthma. Biomedicines. 2021;9(9):1096. https://doi.org/10.3390/biomedicines9091096

34. Maison N, Omony J, Illi S, et al. T2-high asthma phenotypes across lifespan. Eur Respir J. 2022;60(3):2102288. https://doi.org/10.1183/13993003.02288-2021

35. Ignatova GL, Antonov VN, Makarova EA., Kochetkova SA. Experience of using dupilumab in the treatment of severe asthma. Therapeutic Archive. 2020;92(8):95–99. (In Russ). https://doi.org/10.26442/00403660.2020.08.000718

36. Tajiri T, Suzuki M, Nishiyama H, et al. Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study. Allergol Int. 2024;73(3):406–415. https://doi.org/10.1016/j.alit.2024.02.002

37. Tsuge M, Ikeda M, Tsukahara H. Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma. Children (Basel). 2022;9(8):1253. https://doi.org/10.3390/children9081253

38. Scott G, Asrat S, Allinne J, et al. IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline. Cytokine. 2023;162:156091. https://doi.org/10.1016/j.cyto.2022.156091

39. Pelaia C, Pelaia G, Crimi C, et al. Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines (Basel). 2022;10(6):974. https://doi.org/10.3390/vaccines10060974

40. Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486–2496. https://doi.org/10.1056/NEJMoa1804092

41. Jackson DJ, Bacharier LB, Phipatanakul W, et al. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma. Ann Allergy Asthma Immunol. 2023;131(1):44–51.e4. https://doi.org/10.1016/j.anai.2023.03.014

42. Pavord ID, Deniz Y, Corren J, et al. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-toSevere Asthma. J Allergy Clin Immunol Pract. 2023;11(4):1213– 1220.e2. https://doi.org/10.1016/j.jaip.2022.11.043

43. Chuchalin AG, Avdeev SN, Aisanov ZR, et al. Federal guidelines on diagnosis and treatment of bronchial asthma. Pul’monologiya. 2022;32(3):393–447. (In Russ). https://doi.org/10.18093/0869-0189-2022-32-3-393-447

44. Cloutier MM, Baptist AP, Blake KV, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217–1270. https://doi.org/10.1016/j.jaci.2020.10.003

45. Rajvanshi N, Kumar P, Goyal JP. Global Initiative for Asthma Guidelines 2024: An Update. Indian Pediatr. 2024;61(8):781–786.

46. Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018;378(26):2475–2485. https://doi.org/10.1056/NEJMoa1804093

47. Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N Engl J Med. 2021;385(24):2230–2240. https://doi.org/10.1056/NEJMoa2106567

48. Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11–25. https://doi.org/10.1016/S22132600(21)00322-2

49. Corren J, Castro M, O’Riordan T, et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020;8(2):516–526. https://doi.org/10.1016/j.jaip.2019.08.050

50. Bourdin A, Papi AA, Corren J, et al. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. Allergy. 2021;76(1):269–280. https://doi.org/10.1111/all.14611

51. Rabe KF, Pavord ID, Castro M, et al. Dupilumab efficacy and safety in patients with asthma and blood eosinophils 500 cells·μL-1. Eur Respir J. 2022;59(6):2102577. https://doi.org/10.1183/13993003.02577-2021

52. Bleecker ER, Panettieri RA Jr, Lugogo NL, et al. Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils. J Immunol Res. 2023;2023:9943584. https://doi.org/10.1155/2023/9943584

53. Bacharier LB, Guilbert TW, Katelaris CH, et al. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study. J Allergy Clin Immunol Pract. 2024;12(4):948–959. https://doi.org/10.1016/j.jaip.2023.12.006

54. Papadopoulos NG, Szefler SJ, Bacharier LB, et al. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma. Allergy. 2023;78(8):2157– 2167. https://doi.org/10.1111/all.15743

55. Fiocchi AG, Phipatanakul W, Zeiger RS, et al. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. Eur Respir J. 2023;62(5):2300558. https://doi.org/10.1183/13993003.00558-2023

56. Juniper EF, Gruffydd-Jones K, Ward S, Svensson K. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J. 2010;36(6):1410-6. https://doi.org/10.1183/09031936.00117509

57. Lu MA, Eckmann T, Ruvalcaba E, et al. Family management of asthma in Head Start preschool children. Ann Allergy Asthma Immunol. 2022;128(2):178–183. https://doi.org/10.1016/j. anai.2021.11.002

58. Bacharier LB, Maspero JF, Katelaris CH, et al. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study. Lancet Respir Med. 2024;12(1):45–54. https://doi.org/10.1016/S2213-2600(23)00303-X

59. Manti S, Giallongo A, Pecora G, et al. Safety of biologics in severe asthmatic patients with SARS-CoV-2 infection: A prospective study. Pediatr Pulmonol. 2023;58(4):1085–1091. https://doi.org/10.1002/ppul.26298

60. Бурлуцкая А.В., Статова А.В., Долбнева О.В. и др. Эозинофильный эзофагит у детей: клинические случаи // Кубанский научный медицинский вестник. — 2022. — Т. 29. — № 4.— С. 94–106.— https://doi.org/10.25207/1608-6228-2022-29-4-94-106 [Burlutskaya AV, Statova AV, Dolbneva OV, et al. Eosinophilic Esophagitis in Children: Clinical Cases. Kuban Scientific Medical Bulletin. 2022;29(4):94–106. (In Russ). https://doi.org/10.25207/1608-6228-2022-29-4-94-106]

61. Votto M, De Filippo M, Caimmi S, et al. A Practical Update on Pediatric Eosinophilic Esophagitis. Children (Basel). 2023;10(10):1620. https://doi.org/10.3390/children10101620

62. Menard-Katcher C, Furuta GT, Kramer RE. Dilation of Pediatric Eosinophilic Esophagitis: Adverse Events and Short-term Outcomes. J Pediatr Gastroenterol Nutr. 2017;64(5):701–706. https://doi.org/10.1097/MPG.0000000000001336

63. Dowling PJ, Neuhaus H, Polk BI. The Role of the Environment in Eosinophilic Esophagitis. Clin Rev Allergy Immunol. 2019;57(3):330– 339. https://doi.org/10.1007/s12016-018-8697-9

64. Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2020;124(5):416–423. https://doi.org/10.1016/j.anai.2020.03.020

65. Bawany F, Franco AI, Beck LA. Dupilumab: One therapy to treat multiple atopic diseases. JAAD Case Rep. 2020;6(11):1150–1152. https://doi.org/10.1016/j.jdcr.2020.08.036

66. Syverson EP, Rubinstein E. Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center. JPGN Rep. 2022;3(2):e180. https://doi.org/10.1097/PG9.0000000000000180

67. Spergel BL, Ruffner MA, Godwin BC, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022;128(5):589– 593. https://doi.org/10.1016/j.anai.2022.01.019

68. Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):990–1004. https://doi.org/10.1016/S2468-1253(23)00204-2

69. Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med. 2022;387(25):2317–2330. https://doi.org/10.1056/NEJMoa2205982

70. Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024;390(24):2239–2251. https://doi.org/10.1056/NEJMoa2312282

71. McCann E, Chehade M, Spergel JM, et al. Validation of the novel Eosinophilic Esophagitis Impact Questionnaire. J Patient Rep Outcomes. 2023;7(1):120. https://doi.org/10.1186/s41687-023-00654-z

72. Nguyen N, Burger C, Skirka S, et al. One Year Into Dupilumab: Physician and Patient Experiences in Initiating Dupilumab for Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2023;77(4):536–539. https://doi.org/10.1097/MPG.0000000000003901

73. Gangadharan Nambiar G, Rahhal R, Davis BP, et al. Refractory Pediatric Fibrostenotic Eosinophilic Esophagitis Treated With Dupilumab. ACG Case Rep J. 2022;9(11):e00887. https://doi.org/10.14309/crj.0000000000000887

74. Lee CJ, Dellon ES. Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2024;22(2):252–258. https://doi.org/10.1016/j.cgh.2023.08.015